Overexpression of insulin‐like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild‐type SDHB‐negative gastrointestinal stromal tumors
暂无分享,去创建一个
D. Flieder | A. Godwin | J. Schiffman | M. Mehren | L. Rink | M. Belinsky | M. Jahromi
[1] J. Schiffman,et al. Molecular inversion probes: a novel microarray technology and its application in cancer research. , 2012, Cancer genetics.
[2] Kevin B. Jones,et al. Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. , 2012, Cancer genetics.
[3] A. Chou,et al. Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression , 2012, Modern Pathology.
[4] A. D. Dei Tos,et al. Differential expression of neural markers in KIT and PDGFRA wild‐type gastrointestinal stromal tumours , 2011, Histopathology.
[5] P. Rutkowski,et al. Succinate Dehydrogenase-Deficient GISTs: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 66 Gastric GISTs With Predilection to Young Age , 2011, The American journal of surgical pathology.
[6] A. Astolfi,et al. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. , 2011, The American journal of surgical pathology.
[7] W. Sanger,et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin‐fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression , 2011, British journal of haematology.
[8] R. Casadio,et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. , 2011, Journal of the National Cancer Institute.
[9] C. Antonescu,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.
[10] M. Heinrich,et al. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number , 2010, Laboratory Investigation.
[11] P. Bénit,et al. SDHA is a tumor suppressor gene causing paraganglioma. , 2010, Human molecular genetics.
[12] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[13] A. Chou,et al. Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.
[14] Hanlee P. Ji,et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.
[15] W. Young,et al. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases , 2010, The American journal of surgical pathology.
[16] A. Godwin,et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors , 2009, Genes, chromosomes & cancer.
[17] S. Fox,et al. No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. , 2009 .
[18] E. Capriotti,et al. Functional annotations improve the predictive score of human disease‐related mutations in proteins , 2009, Human mutation.
[19] T. Pajak,et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor , 2009, Molecular Cancer Therapeutics.
[20] Hanlee P. Ji,et al. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. , 2009, Cancer genetics and cytogenetics.
[21] A. D. Van den Abbeele,et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.
[22] A. Hartmann,et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours , 2009, Journal of Clinical Pathology.
[23] P. Spellman,et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.
[24] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Narasimhan P. Agaram,et al. Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.
[26] A. Godwin,et al. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors , 2008, Cell cycle.
[27] D. Flieder,et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.
[28] Narasimhan P. Agaram,et al. Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.
[29] James Ireland,et al. Analysis of molecular inversion probe performance for allele copy number determination , 2007, Genome Biology.
[30] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[31] J. Fletcher,et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.
[32] C. Stratakis,et al. Familial gastrointestinal stromal tumors and germ-line mutations. , 2007, The New England journal of medicine.
[33] E. Campo,et al. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. , 2007, The Journal of clinical endocrinology and metabolism.
[34] I. Hassinen,et al. Inhibition of Hypoxia-inducible Factor (HIF) Hydroxylases by Citric Acid Cycle Intermediates , 2007, Journal of Biological Chemistry.
[35] E. Gottlieb,et al. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.
[36] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[37] Ronald W. Davis,et al. Allele quantification using molecular inversion probes (MIP) , 2005, Nucleic acids research.
[38] Sandro Santagata,et al. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.
[39] Adrian A Canutescu,et al. Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.
[40] N. Socci,et al. Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.
[41] J. Fletcher,et al. KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.
[42] S. Antonarakis,et al. Mutation Nomenclature , 2003, Current protocols in human genetics.
[43] Long-Cheng Li,et al. MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..
[44] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[45] S. Antonarakis,et al. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .
[46] J. Carney,et al. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. , 1999, Mayo Clinic proceedings.
[47] K. Chorneyko,et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. , 1999, The American journal of surgical pathology.
[48] L. Kindblom,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.
[49] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[50] S. Sheps,et al. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. , 1977, The New England journal of medicine.
[51] M. O'sullivan,et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors , 2011, Modern Pathology.
[52] Jean-Yves Scoazec,et al. BRAF mutation status in gastrointestinal stromal tumors. , 2010, American journal of clinical pathology.
[53] Hanlee P. Ji,et al. Molecular inversion probe assay for allelic quantitation. , 2009, Methods in molecular biology.
[54] J. Ellison,et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.
[55] Mostafa Ronaghi,et al. Molecular inversion probe assay. , 2007, Methods in molecular biology.
[56] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[57] M. Waters,et al. of Insulin-Like Growth , 1993 .
[58] M. Heinrich,et al. Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target , 2009, International journal of cancer.